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Abstract
Background: To investigate the effect of baseline clinical characteristics and glucocorticoid treatment on temporal
artery biopsy (TAB) findings in patients with giant cell arteritis (GCA).
Methods: Individuals who developed GCA after inclusion in two population-based health surveys were identified
through linkage to the local and the national patient registers. In addition, other patients diagnosed with GCA at
the Departments of Internal Medicine and Rheumatology at an area hospital were included. A structured review of
medical records and TAB pathology reports was performed. The presence or absence of giant cells, granuloma,
fragmented internal elastic lamina, fibrosis and grade of inflammatory infiltrates were recorded.
Results: In 183 cases with a confirmed clinical diagnosis of GCA, 139 were biopsied after start of glucocorticoids
(median treatment duration 3 days; interquartile range 2–5). Patients with a positive TAB (77 %) had significantly
higher C-reactive protein (CRP; p = 0.007) and erythrocyte sedimentation rate (ESR; p = 0.03) at the time of clinical
diagnosis. A positive TAB tended to more common in women, but there was no difference in the proportion of
patients with polymyalgia rheumatica or visual symptoms.
Patients biopsied before or on the same day as initial treatment where more likely than those biopsied 1–3 days
after treatment start to have positive biopsy [odds ratio (OR) 2.86; 95 % CI 1.06–7.70] as well as inflammatory
infiltrates (OR 3.30; 95 % CI 1.15–9.49).
There was no significant difference in the proportions of a fragmented internal lamina (p = 0.86), giant cells (p = 0.
10), granuloma (p = 0.19), minor inflammatory infiltrates (p = 0.47), major inflammatory infiltrates (p = 0.09), or overall
positive biopsy (p = 0.17) report by treatment duration comparing: ≤ 0 days, 1–3 days, 4–6 days, 7–28 days. Among
those biopsied 7–28 days after start of treatment, 80 % of TABs were positive, and histopathology features were not
substantially different from those biopsied after shorter glucocorticoid treatment.
Conclusion: Biopsies were more likely to be positive and have characteristic histopathologic features in patients
with high CRP and ESR, and prior to start of corticosteroid treatment TABs taken 1–4 weeks after initiation of
glucocorticoid treatment reveal changes consistent with GCA and therefore still yields clinically useful information
for the diagnosis.
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Background
Clinical findings as well as histopathologic evidence of
vasculitis are used for the diagnosis of giant cell arteritis
(GCA). Temporal artery biopsy (TAB) is often employed
in diagnosing GCA and in excluding other conditions.
Previous studies have shown that higher C-reactive
protein (CRP) [1], erythrocyte sedimentation rate (ESR)
[1, 2], thrombocytosis [1, 3] and anemia [2] are predict-
ive for a TAB result compatible with GCA. Furthermore,
higher age [4, 5], ethnicity [5] as well as an abnormal
temporal artery on physical examination and constitu-
tional symptoms [3] have been found to be significant
predictors for a positive TAB in some studies, although
others have failed to demonstrate a significant correl-
ation between age, ethnicity or ESR and findings on
TAB [6].
The Initial Systemic Inflammation Reaction (ISIR) is a
measure of inflammation scored by the presence of the
following five parameters: fever, anemia, thrombocytosis,
leucocytosis and ESR > 100 mm/h [7]. The finding on
TAB of inflammatory infiltrates confined to the adventi-
tia at diagnosis has been correlated with lower levels of
ISIR and a tendency towards a faster rate of glucocortic-
oid discontinuation [7].
There are conflicting data on the effect of glucocortic-
oid treatment on TAB findings in patients with GCA.
An early study on the subject showed that biopsy find-
ings were partly masked after only one week of gluco-
corticoid treatment [8]. Other studies have on the
contrary shown changes consistent with temporal arter-
itis in TAB specimens from patients biopsied two [6, 9]
or four [4] weeks of glucocorticoid treatment. Finally, re-
cent preliminary reports from a multicentre study have
reported a rapid resolution of the temporal artery halo
signs demonstrated on ultrasonography [10] and a wide
variety of TAB findings [11] after short term (mainly ≤
1 week) glucocorticoid treatment.
Font and co-workers concluded that, although some
signs of inflammation remained after long-term treat-
ment, glucocorticoid treatment caused changes in the
histological features of TAB [12]. In all 35 GCA cases in
their study, a mix of lymphocytes with mononuclear
cells and epithelioid histiocytes located in the outer
muscle layer and the adventitia, as well as loss of the in-
ternal elastic lamina were observed. The likelihood of
finding diffuse infiltrates in the arterial wall and giant
cells was lower if the patient had been on glucocorticoid
treatment for more than 14 days.
The interpretation of TAB findings is a key issue for
the management of GCA. The purpose of this study was
to investigate histopathology features in TAB from a
well-defined group of patients with a clinical diagnosis
of GCA, and assess how these features relate to baseline




Incident cases of GCA among participants in two
population-based surveys performed in the same catch-
ment area as well as other patients with a diagnosis of
GCA at a single centre, the University hospital, which
provides all primary and secondary inpatient care in the
area, were included in the present study. The two
population-based health surveys were performed in
Malmö, Sweden (current population 318,000; population
during the screening period 1974–1996 between 229,000
and 247,000). Details on the Malmö Diet and Cancer
Study (MDCS, N = 30447 subjects; 12121 men/18326
women) and the Malmö Preventive Medicine Project
(MPMP, N = 33346; 22444 men/10902 women) have
been described elsewhere [13–15]. Patients with a regis-
tered diagnosis of GCA after inclusion in the MDCS and
through December 31, 2011 were identified in a study
investigating predictors of GCA, as previously described
[15]. Preliminary findings on TAB features in a subset of
the included patients have been reported previously [16].
In addition to the incident cases in the MDCS and the
MPMP, all other cases with a registered GCA diagnosis
in the outpatient clinical administrative register between
1993 and 2008 at the Department of Rheumatology and
between 1998 and 2008 at the Department of Internal
Medicine at Malmö University Hospital were included
in the study sample.
The medical records of the identified patients were
subjected to a structured review. Inclusion in the present
study required a validated diagnosis of GCA, based on
available medical records and expert opinion. In
addition, cases were classified according to the American
College of Rheumatology (ACR) 1990criteria for the
classification of GCA [17]. The 1990 ACR classification
criteria were not mandatory for inclusion in this study.
Some cases with typical clinical features but limited data
regarding some parameters were included even though
they didn’t fulfill the criteria.
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Data collection
The date of diagnosis was defined as the day when a ten-
tative clinical diagnosis was made and glucocorticoid
treatment was started. Clinical data regarding GCA ex-
tracted from clinical records included information corre-
sponding to the ACR criteria, i.e. age, new headache,
abnormality on physical examination of the temporal
arteries, ESR and results of the TAB. In addition, the
following data at the time of diagnosis were collected
according to a structured protocol: CRP, haemoglobin,
platelets count, smoking history, family history of
rheumatic diseases, documented symptoms of polymyal-
gia rheumatica (PMR) at diagnosis, visual symptoms (de-
fined as all reported new onset visual problems not
explained by other factors than GCA) and permanent
visual impairment, and the initial dose of glucocorticoids
including initial intravenous treatment if given. Informa-
tion on large vessel involvement and all vascular imaging
studies performed up to the date of record review was
also noted.
All cases with a confirmed clinical diagnosis of GCA,
adequate TAB according to the pathologist and details
available regarding dates of performing TAB and start of
glucocorticoid treatment were included in this study. Of
228 incident cases, 183 fulfilled the criteria above and
were included in the present investigation. The reasons
for exclusion were: no adequate biopsy (n = 21); lack of
information on date of start of glucocorticoids (n = 6);
lack of information date of TAB (n = 31).
A structured review of TAB pathology reports for all
identified cases was performed. The biopsies were
mainly performed by otorhinolaryngologists who had ac-
cess to a summary report from the referring physician.
This report usually included a short medical history,
current symptoms and information regarding treatment
with glucocorticoids. The presence or absence of the fol-
lowing histopathology features was recorded: giant cells,
granuloma, fragmented internal elastic lamina, inflam-
matory infiltrates and fibrosis. Major inflammatory infil-
trates were defined as the presence of a large number of
inflammatory cells in several layers of the vascular wall
(adventitia/media/intima). In the absence of a detailed
description of all layers, lesions described as “massive
inflammation”, “typical GCA” or using similar wording
were classified as major inflammatory infiltrates,
whereas those described as “limited infiltrates”, “minor
inflammation” etc. were classified as minor inflammatory
infiltrates. All reports were reviewed by two of the
authors (KJ and CT). The final judgment was based on
consensus.
Statistical analysis
Baseline parameters in TAB positive vs. TAB negative
patients were compared using chi-square test, Student’s
T test (for continuous parameters with a normal distri-
bution) and the Mann-Whitney U test (for continuous
parameters with a skewed distribution). The relationship
between reported histopathology features and overall
positive biopsy in those biopsied before start of treat-
ment or on the same day, after 1–3 days, after 4–6 or
after 7–28 days of glucocorticoid treatment was analysed
using the chi-square test. Two cases with a very long
duration (35 and 253 days) from the time of initiation of
treatment to time of TAB were not included in the as-
sessment of duration between initial treatment and TAB.
Logistic regressions were performed analysing clinical
characteristics of TAB positive vs. TAB negative patients
as well as those with and without reported inflammation
on pathology reports. In analyses by category of time on
glucocorticoids before TAB, the group that had been
treated for 1–3 days was used as the reference, as this
may reflect standard of care with prompt initiation of
treatment and an early TAB. The Mann-Whitney U test
was used to assess differences in the distribution of cat-
egory of time on treatment with glucocorticoids among
those with vs. without specific histopathology features.
Results
A total of 183 cases with confirmed GCA, a representa-
tive TAB and information available regarding the time
between TAB and glucocorticoid treatment start were
included (Table 1). 102 cases were recruited from the re-
view of the participants in the population based health
surveys, and 81 patients from the local clinical adminis-
trative registery.
The median time from start of glucocorticoid treat-
ment to TAB was 3 days [interquartile range (IQR) 2–5;
maximum 253 days]. No patient received other im-
munosuppressive drugs before the TAB. 44 patients
(24 %) were biopsied either before glucocorticoids were
initiated or on the same day. For these, the median time
from TAB to treatment start was 2 days [IQR 0–3.75;
maximum 22 days]. Patients with a positive biopsy (141
of 183, 77 %) had significantly higher CRP (median
101 mg/l; IQR 70–145 vs. median 70, IQR 28–119; p =
0.007) and ESR (mean 83.1 mm/1 hr, SD 27.1 vs. mean
72.6, SD 23.2; p = 0.03) at the time of clinical diagnosis
(Table 2).
Comparison of those who underwent TAB before or after
starting glucocorticoid therapy
There was a greater proportion of women among those
who were biopsied before or on the same day as initi-
ation of glucocorticoid treatment, compared to those bi-
opsied after treatment start (p = 0.02). The subset with a
pre-treatment biopsy also had higher ESR (median 88 vs.
78; p = 0.04), but not CRP, levels at baseline. They were
also less likely to have visual impairment at diagnosis
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(36 % vs. 54 %; p = 0.04), and they were treated with
a lower dosage of oral glucocorticoids (median
40 mg/day; IQR 40–50 vs. median 50 mg/day; IQR
40–60; p = 0.005).
Timing of TAB in relation to histopathology findings
Two cases with a very long duration (35 and 253 days)
from the time of initiation of treatment to time of TAB
were not included in the assessment of duration between
initial treatment and TAB. Both these patients had a
positive TAB and fulfilled the ACR criteria for GCA.
TAB revealed inflammatory infiltrates and fragmented
internal elastic lamina in both, and one had giant cells.
We compared pathology report findings in patients
who started treatment with glucocorticoids after TAB or
on the same day with those who had been treated for 1–3
days, 4–6 days and 7–28 days (Table 3). Overall, the
interobserver agreement in the pathology report review
was 93 %, ranging from 100 % (for the presence/absence
of granuloma) to 78 % (for inflammatory infiltrates:
major/minor/none) for the different features studied.
Patients who had a biopsy before treatment was initi-
ated were more likely to have inflammatory infiltrates
than those biopsied at a later time point. There was no
significant difference in the distribution of proportions
of positive TAB results between the four groups (p =
0.17). The lowest probability of finding inflammatory in-
filtrates overall, major inflammatory infiltrates and giant
cells was in those treated for 1–3 days prior to biopsy.
Patients in this group were also the most likely to have
been treated with intravenous glucocorticoids prior to
biopsy (12 individuals (16 %) vs. 3 (7 %) and 2 (10 %) in
the groups with total pre-biopsy glucocorticoid treat-
ment of 4–6 and 7–28 days, respectively). The dose of
Table 1 Characteristics of patients with giant cell arteritis undergoing temporal artery biopsy
Number of patients 183
Female sex 134 (73 %)
Age at GCA diagnosis (years) (mean) 74.3 (SD 8.97; range 49–95)
Positive biopsy 141 (77 %)
Fulfilled ACR criteria 175 (96 %)
Visual symptoms at diagnosis 91 (50 %)
Permanent visual loss 22 (12 %)
ESR at diagnosis (mm/h) (mean) 81 (SD 26.6)
Initial glucocorticoid dose (mg prednisolone) Median 40 (IQR 40–60); Mean 51 (SD 37.3)
CRP at diagnosis (mg/l) (median) 99 (IQR 56–143)
Large vessel involvement during follow-up 22 (12 %)
GCA giant cell arteritis, ACR American College of Rheumatology, ESR erythrocyte sedimentation rate, CRP C-reactive protein, SD standard deviation, IQR
interquartile range
Table 2 Baseline features at time of diagnosisa in patients with GCA with positive vs. negative biopsy
Feature Biopsy positive (n = 141) Biopsy negative (n = 42) p
Age at GCA diagnosis (years) 74.3 (SD 8.8; range 49–95) 74.4 (SD 9.5; range 54–93) 0.94
Female sex 108 (77 %) 26 (62 %) 0.06
ESR mm/h; mean (SD)b 83.1 (27.1) 72.6 (23.2) 0.03
CRP mg/l; median (IQR)b 101 (70–145) 70 (28–119) 0.007
Time from glucocorticoid treatment to TAB, days (median; IQR) 2 (0–4) 2 (1–5) 0.62
Initial steroid dose, mg (median; IQR)b 40 (40–60) 50 (40–60) 0.18
Symptoms of PMR at diagnosis 38 (27 %) 15 (36 %) 0.27
Visual symptoms at diagnosis 68 (48 %) 23 (55 %) 0.46
Permanent visual impairment 20 (14 %) 2 (5 %) 0.10
Current smokingb 73 (52 %) 25 (60 %) 0.43
Ever smokingb 103 (73 %) 32 (76 %) 0.83
Large vessel involvement during the follow-up 19 (13 %) 3 (7 %) 0.27
ESR erythrocyte sedimentation rate, CRP C-reactive protein, PMR polymyalgia rheumatica, SD standard deviation, IQR interquartile range
aDefined as the day when a tentative clinical diagnosis was made and glucocorticoid treatment was started
bAvailable data from 171 patients on ESR, 136 patients on CRP, prednisolone dose available from 177 patients, current smoking at diagnosis from 98 patients and
from 135 patients on ever smoking
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intravenous glucocorticoids was usually 500 mg methyl-
prednisolone per day, given for 1–3 days.
There were no significant differences in the propor-
tions with a fragmented internal elastic lamina, giant
cells, granuloma, or overall positive biopsy report by
treatment duration (Table 3). There were no differences
in the distribution of category of time on treatment with
glucocorticoids for the presence of any of the histopath-
ology features investigated, including major or minor
inflammatory infiltrates (Table 3).
Predictors for positive findings in TAB
By bivariate logistic regression, TAB performed before or
on the same day as initial treatment was associated with
histologic findings consistent with GCA (OR 2.86; 95 %
CI 1.06–7.70) compared to those biopsied 1–3 days after
treatment initiation, although this association did not
reach statistical significance in analysis adjusted for sex
(OR 2.54; 95 % CI 0.93–6.96). Women tended to be
more likely to have a positive biopsy (OR 2.01; 95 % CI
0.97–4.20). This pattern was less marked in analysis ad-
justed for category of time on glucocorticoids (OR 1.73;
95 % CI 0.81–3.68). There were no differences in age at
diagnosis or number of days from glucocorticoid treat-
ment to TAB in analyses comparing patients with positive
vs. negative biopsy. Neither current nor ever smoking
were predictive of a positive biopsy (Table 4).
Patients in the highest quartile of ESR (100–150 mm/
1 h) were four times more likely to have a positive biopsy
(OR 4.27; 95 % CI 1.09–16.82), as were patients with CRP
levels between 99 and 143 mg/l (third quartile) (OR 4.64;
95 % CI 1.33–16.23), compared to those in the lowest
quartile of ESR and CRP, respectively. There was a pro-
gressively increasing chance of a positive biopsy with
higher quartiles of ESR (p for trend: 0.01), and a similar
tendency for CRP (p for trend: 0.07). The distribution of
males and females was similar in quartiles of both ESR
and CRP (data not shown).
Female sex tended to be a predictor for the presence
of inflammatory infiltrates in pathology report (Table 5).
Biopsy specimens from patients who underwent TAB
before start of glucocorticoids, or on the same day as
treatment initiation were significantly more likely to
have inflammatory infiltrates (OR 3.30; 95 % CI 1.15-
9.49) compared to those biopsied after 1–3 days of treat-
ment. High CRP (third or fourth quartile, i.e. ≥ 99 mg/l)
was also predictive of inflammatory infiltrates in the
TAB, but there was no such association with ESR
(Table 5). Higher quartiles of ESR and CRP were sig-
nificantly associated with a progressively greater likeli-
hood of presence of inflammatory infiltrates (p = 0.03
and p = 0.01, respectively).
In logistic regression models using the category of
patients biopsied before start of glucocorticoids as
reference, there was no linear progression of the odds
ratio for positive biopsy (Additional file 1: Table S1) or for
inflammatory infiltrates (Additional file 1: Table S2).
Discussion
In this study of a population-based sample of patients
with a clinical diagnosis of GCA, we found no significant
change in the TAB results with longer time on glucocor-
ticoids. Importantly, histopathology features in those
biopsied 7–28 days after start of treatment were not sub-
stantially different from those biopsied after shorter
glucocorticoid treatment. Patients who were biopsied be-
fore or on the same day as initial treatment were more
likely than those biopsied shortly (1–3 days) after initi-
ation of treatment to have a positive biopsy, as well as in-
flammatory infiltrates on TAB. The group treated for 1–3
days with glucocorticoids had the lowest probability for a
positive biopsy report, presence of major inflammatory
Table 3 Features recorded in pathology reports, stratified by time from initiation of glucocorticoid treatment to biopsy
Time from treatment start to
biopsy
≤0 days 1-3 days 4-6 days 7-28 days p p for
trend *(n = 44) (n = 74) (n = 43) (n = 20)
Inflammatory infiltrates 39 (89 %) 52 (70 %) 35 (81 %) 15 (75 %) 0.12 0.95
Biopsy positive 38 (86 %) 51 (69 %) 34 (79 %) 16 (80 %) 0.17 0.64
Fragmented internal elastic lamina 20 (45 %) 33 (45 %) 21 (49 %) 10 (50 %) 0.86 0.65
Giant cells 21 (48 %) 23 (31 %) 23 (53 %) 8 (40 %) 0.10 0.73
Granuloma 9 (20 %) 6 (8 %) 4 (9 %) 3 (15 %) 0.19 0.28
Fibrosis 4 (9 %) 15 (20 %) 8 (19 %) 4 (20 %) 0.47 0.24
Minor inflammatory infiltrates a 13 (30 %) 27 (36 %) 14 (33 %) 6 (30 %) 0.87 0.94
Major inflammatory infiltrates b 23 (52 %) 23 (31 %) 21 (49 %) 9 (45 %) 0.09 0.90
aLesions described as “limited infiltrates”, “minor inflammation” etc. were classified as minor inflammatory infiltrates
bLesions described as “massive inflammation”, “typical GCA” or using similar wording were classified as major inflammatory infiltrates
*The Mann–Whitney U test was used to assess differences in the distribution of category of time on treatment with glucocorticoids among those with vs. without
specific histopathology features
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infiltrates and giant cells. Possibly, early high glucocortic-
oid exposure could contribute to this pattern. This in-
cludes intravenous treatment, which was slightly more
frequent among those biopsied after 1–3 days. However,
Font et al. compared 6 patients with intravenous
treatment to 29 who received oral glucocorticoids
only, and did not find any differences in histopath-
ology findings [12]. The mean oral starting dose of
glucocorticoids in that study (74 mg/day) was sub-
stantially higher than the average starting dose given
in this study (51 mg/day) [12]. Unfortunately, data on
the tapering of glucocorticoids are not available from
the present study.
Women tended to be more likely to have a positive bi-
opsy, but neither current nor ever smoking was predict-
ive of biopsy findings. Higher quartiles of ESR and CRP
were predictive for positive biopsy, and in the case of
CRP also for the presence of inflammatory infiltrates.
We did not find any association between age, initial
glucocorticoid dose, symptoms of PMR or visual symp-
toms at time of diagnosis and biopsy positivity. Cases
biopsied before or on the same day as initiation of gluco-
corticoids were more often female, had significantly
higher ESR and were less likely to have visual impair-
ment at diagnosis.
The reason that women were more likely to undergo
TAB before or on the same day as initial treatment is
unclear. It may be that because GCA is more common
in women, the diagnosis may be suspected earlier than
in men. This observation could also reflect differences in
presentation between male and female patients with
GCA. This should be further explored.
In the present study, as many as 50 % of the patients
had visual symptoms at the time of diagnosis. This figure
is higher than that reported in most previous studies
[18, 19]. On the other hand, the proportion of patients
with permanent visual impairment was slightly lower
compared to what has been reported previously [19].
This likely reflects that most of the patients in the
present study received adequate treatment with gluco-
corticoids as soon as the diagnosis was suspected, in
particular when visual symptoms were present.
Table 4 Potential predictors at time of diagnosisa for positive temporal artery biopsy in patients with GCA
Feature Odds ratio 95 % CI p
Sex (female vs male) 2.01 0.97–4.20 0.06
Age (per year) 1.00 0.96–1.04 0.94
Time from glucocorticoid treatment to TAB (per day) 1.02 0.95–1.09 0.65
Current smoking vs non-current smokingb 0.74 0.35–1.56 0.43
Ever smoking vs never smokingb 0.90 0.36–2.28 0.83
ESR (per mm/h) 1.02 1.00–1.03 0.04
CRP (per mg/l) 1.01 1.00-1.02 0.01
Time from glucocorticoid treatment to TAB
< 1 dayc 2.86 1.06–7.70 0.04
1–3 days 1.00 (reference)
4–6 days 1.70 0.70–4.13 0.24
7–28 days 1.80 0.54–6.00 0.34
ESR (mm/h) * b
Quartile 1 (20–61) 1.00 (reference)
Quartile 2 (62–79) 0.45 0.17-1.20 0.11
Quartile 3 (80–99) 1.14 0.43-3.01 0.80
Quartile 4 (100–150) 4.27 1.09-16.82 0.04
CRP (mg/l) ** b
Quartile 1 (4–56) 1.00 (reference)
Quartile 2 (57–98) 2.89 0.94-8.86 0.06
Quartile 3 (99–142) 4.64 1.33-16.23 0.02
Quartile 4 (143–478) 2.39 0.81-7.04 0.12
TAB temporal artery biopsy, ESR erythrocyte sedimentation rate, CRP C-reactive protein, CI confidence interval
* p for trend 0.01
** p for trend 0.07
aDefined as the day when a tentative clinical diagnosis was made and glucocorticoid treatment was started
bAvailable data: ESR from 171 patients; CRP 136 patients; current smoking at diagnosis 98 patients; ever smoking 135 patients.
cIncludes individuals biopsied before start of glucocorticoid treatment
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Font et al. [12] found that patients with GCA who had
been treated with glucocorticoids for more than 14 days
before the TAB had inflammatory infiltrates that were
limited to the adventitia-media junction, whereas those
with shorter treatment were more likely to have diffuse
infiltrates. By contrast, we found that major inflamma-
tory infiltrates did not seem to respond rapidly to
treatment. Neither could we confirm their findings sug-
gesting that giant cells vanished after even a few days of
treatment, as the proportion with documented giant
cells in the TAB in our study was similar among those
biopsied after 7–28 days of glucocorticoid treatment
compared to those with an earlier TAB. These discrep-
ancies may be explained partly by differences in gluco-
corticoid dose (see above), and also by methodological
differences, in particular case ascertainment. Font et al.
defined positive biopsy by inflammatory infiltrates con-
taining both lymphocytes and epithelioid histiocytes,
whereas in our cases the histopathology was judged con-
sistent with GCA based on the overall impression of the
clinical pathologist. Furthermore, geographic differences
and differences in sample size (183 patients in the
present study compared to 35 in the study by Font et al.)
may contribute to the difference in findings.
Our results suggest that glucocorticoid treatment do
not significantly affect the features of inflammation seen
in TAB the first weeks of treatment. Deng et al. have
suggested that some specific parts of the inflammation
might persist during treatment while other parts might
respond more rapidly, reporting that glucocorticoids
down-regulate IL-17 production by Th17 cells, while
Th1 cells producing interferon-γ- persist despite long
term treatment [20]. This is a hypothesis that cannot be
confirmed or rejected by the present study, and should
be further investigated.
A limitation of this study is that information regarding
TAB histopathology was collected from pathology reports
only. Another limitation of this study is that the pathology
reports were collected over an extended period, 1974–
2011. The pathologists’ interpretation and description of
the TAB reports may have changed over time. Strengths
of the study include the population-based approach,
Table 5 Potential predictors at time of diagnosis for inflammatory infiltrates recorded in pathology reports
Feature Odds ratio 95 % CI p
Sex (female vs male) 1.93 0.91–4.06 0.09
Age (per year) 1.01 0.97–1.05 0.61
Time from glucocorticoid treatment to TAB (per day) 1.01 0.96–1.07 0.66
Current smoking vs non-current smokingc 0.65 0.30–1.41 0.27
Ever smoking vs never smokingc 0.62 0.22–1.75 0.37
ESR (per mm/h) 1.01 1.00–1.03 0.05
CRP (per mg/l) 1.01 1.00–1.02 0.01
Time from glucocorticoid treatment to TAB
< 1 dayd 3.30 1.15–9.49 0.03
1-3 days 1.00 (reference)
4-6 days 1.90 0.74–4.62 0.19
7-28 days 1.27 0.41–3.92 0.68
ESR (mm/h) a,c
Quartile 1 (20–61) 1.00 (reference)
Quartile 2 (62–79) 0.51 0.19–1.36 0.18
Quartile 3 (80–99) 1.14 0.43–3.01 0.80
Quartile 4 (100–150) 3.13 0.90–10.90 0.07
CRP (mg/l) b,c
Quartile 1 (4–56) 1.00 (reference)
Quartile 2 (57–98) 2.89 0.94–8.86 0.06
Quartile 3 (99–142) 4.64 1.33–16.23 0.02
Quartile 4 (143–478) 3.60 1.11–11.62 0.03
TAB temporal artery biopsy, ESR erythrocyte sedimentation rate, CRP C-reactive protein, CI confidence interval
a p for trend 0.03
b p for trend 0.01
cAvailable data: ESR from 171 patients; CRP 136 patients; current smoking at diagnosis 98 patients; ever smoking 135 patients
dIncludes individuals biopsied before start of glucocorticoid treatment
Jakobsson et al. BMC Musculoskeletal Disorders  (2016) 17:363 Page 7 of 8
reflecting that the patients are representative for GCA
cases managed in the area, and the availability of complete
medical information and histopathology data.
Conclusions
Biopsies were more likely to be positive and have charac-
teristic histopathologic features in GCA in patients with
high CRP and ESR, and when the biopsy was performed
prior to start of glucocorticoid treatment. TABs taken 1–4
weeks after starting glucocorticoids still reveal changes
consistent with GCA, including inflammatory infiltrates
and/or giant cells, in a majority of patients with a clinically
suspected diagnosis. Delayed TAB still yields clinically
useful information for the diagnosis of GCA.
Additional file
Additional file 1: Table S1. Potential predictors at time of diagnosis*
for positive temporal artery biopsy in patients with GCA. Table S2.
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